Evidence map›Paper›PMID 32285259›Full record

ArticleClinical rheumatology2020

Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.

A B Azuaga, B Frade-Sosa, A Laiz, P Estrada, A Prior-Español, L Horcada, L Polino, M Moreno, C Moragues, A Urruticoechea-Arana and 16 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Psoriatic Arthritis: From Diagnosis to Treatment.Journal of clinical medicine · 2025
    Review
  3. Review
  4. Psoriatic Arthritis: Pathogenesis and Targeted Therapies.International journal of molecular sciences · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 1 country.

A B AzuagaArthritis Unit, Rheumatology Department, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
B Frade-SosaArthritis Unit, Rheumatology Department, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
A LaizRheumatology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
P EstradaRheumatology Department, Hospital Moisès Broggi, Barcelona, Spain.
A Prior-EspañolRheumatology Department, Hospital Germans Trias i Pujol, Barcelona, Spain.
L HorcadaRheumatology Department, Hospital Navarra, Pamplona, Spain.
L PolinoRheumatology Department, Hospital del Mar, Barcelona, Spain.
M MorenoRheumatology Department, Hospital Universitari Parc Taulí, I3PT, UAB, Sabadell, Spain.
C MoraguesRheumatology Department, Hospital Platò, Barcelona, Spain.
A Urruticoechea-AranaRheumatology Department, Hospital Can Misses, Ibiza, Spain.
A SellasRheumatology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
J L TandaipanRheumatology Department, Hospital Universitari Mútua Terrassa, Barcelona, Spain.
V Torrente-SegarraRheumatology Department, Hospital l'Alt Penedès, Barcelona, Spain.
J Garcia-MiguelRheumatology Department, Hospital Universitari Sagrat Cor, Barcelona, Spain.
I RosRheumatology Department, Hospital Son Llàtzer, Mallorca, Spain.
S OrdoñezRheumatology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
P MoyaRheumatology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
D ReinaRheumatology Department, Hospital Moisès Broggi, Barcelona, Spain.
L Mateo-SoriaRheumatology Department, Hospital Germans Trias i Pujol, Barcelona, Spain.
C FitoRheumatology Department, Hospital Navarra, Pamplona, Spain.
E BeltránRheumatology Department, Hospital del Mar, Barcelona, Spain.
M PujolRheumatology Department, Hospital Universitari Mútua Terrassa, Barcelona, Spain.
A M CuervoArthritis Unit, Rheumatology Department, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
J D CañeteArthritis Unit, Rheumatology Department, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
Julio RamírezArthritis Unit, Rheumatology Department, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain. julramga@gmail.com.
ESPOCAT group
Hospital Clínic de Barcelona · ESHospital de Sant Pau · ESHospital Del Mar · ESHospital Universitari Arnau de Vilanova · ESHospital de Sant Joan Despí Moisès Broggi · ESHospital Universitari Germans Trias i Pujol · ESMútua Terrassa · ESHospital Can Misses · ESHospital Plató · ESHospital Son Llatzer · ESHospital Universitari Sagrat Cor · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effectiveness and survival of ustekinumab (UST) among patients with psoriatic arthritis (PsA) treated under routine clinical care.

methodsMulticenter study. Epidemiological and clinical data was collected through electronic medical records of all patients with PsA who started UST in 15 hospitals of Spain.

resultsTwo hundred and one patients were included, 130 (64.7%) with 45 mg and 71 (35.3%) with 90 mg. One hundred and thirty one patients (65.2%) had previously received another biological therapy. The median baseline DAS 28 ESR was 3.99, and Psoriasis Area and Severity Index (PASI) was 3. Overall, there was a significant decrease in DAS66/68 CRP, swollen joint count (SJC), tender joint count (TJC), and PASI in the first month of treatment, with earlier improvement in skin (PASI) than joints outcomes. Survival was numerically lower in patients with UST 45 mg (58.1%) than 90 mg (76.1%), although significant differences were not found (p = 0.147). When comparing naïve and < 1 TNF blocker versus > 2 TNF blocker-experienced patients, a significantly earlier response was seen in the former group regarding SJC (p = 0.029) at 1 month. Fifty-one patients (25.3%) stopped UST due to joint inefficacy and 4 patients due to adverse events (1.9%). Drug survival was significantly better in patients with fewer lines of previous biological agents (p = 0.003 for < 1 TNF blocker versus > 2 TNF blocker users).

conclusionsUST was effective in PsA patients in a routine clinical care setting. Patients with UST 90 mg and fewer lines of previous biologics achieved better and faster responses. Key Points • Largest cohort of patients with PsA in treatment with UST with specific rheumatological indication. • First cohort of patients with PsA comparing effectiveness of UST according to 45/90 mg dose.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticPsoriasisHumansSeverity of Illness IndexSpainTreatment OutcomeUstekinumabAntirheumatic AgentsUstekinumabPsoriatic arthritisTumor necrosis factorUstekinumab

Identifiers

PMID32285259
OpenAlexW3015812903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.